Skip to main content
Article
A Pilot, Double-Blind, Placebo-Controlled Trial of Pregabalin (Lyrica®) in the Treatment of Essential Tremor
Movement Disorders (2007)
  • Theresa A. Zesiewicz, University of South Florida
  • Christopher L. Ward, University of South Florida
  • Robert A. Hauser, University of South Florida
  • Jason L. Salemi, University of South Florida
  • Shaila Siraj, University of South Florida
  • Maria-Carmen Wilson, University of South Florida
  • Kelly L. Sullivan, Georgia Southern University
Abstract

We performed a pilot, double-blind, placebo-controlled, randomized trial to evaluate the efficacy and tolerability of pregabalin (PGB, Lyrica), an antiepileptic agent, in treating essential tremor (ET). Twenty two patients with ET were randomly assigned to receive PGB or placebo. PGB was initiated at 50 mg/day and was escalated by 75 mg/day every 4 days to a maximum dose of 600 mg/day. Patients were evaluated by accelerometry and the Fahn–Tolosa–Marin (FTM) rating scale. There was a significant reduction in tremor amplitude in the PGB group compared with the placebo group, as measured by accelerometry, at a mean dose of 286.76 ± 100.05 mg/day. Action tremor limb scores on the FTM also improved in the PGB group compared with the placebo group (P-value for multilevel modeling = 0.04). PGB was fairly well tolerated, with about one-third of patients dropping out of the study because of adverse events. PGB provided significant improvements in accelerometry and in action tremor limb scores on the FTM. However, larger studies are needed to further evaluate the potential effect of PGB on ET.

Keywords
  • Pregabalin,
  • Lyrica,
  • Essential tremor
Disciplines
Publication Date
2007
Citation Information
Theresa A. Zesiewicz, Christopher L. Ward, Robert A. Hauser, Jason L. Salemi, et al.. "A Pilot, Double-Blind, Placebo-Controlled Trial of Pregabalin (Lyrica®) in the Treatment of Essential Tremor" Movement Disorders Vol. 22 Iss. 11 (2007)
Available at: http://works.bepress.com/kelly_sullivan/7/